Oral Safe and Super Pure 99% Dipeptidyl Peptidase IV Inhibitor SYR-472/ Trelagliptin Succinate CAS 1029877-94-8 for Treatment of Type 2 Diabetes
Other Name: SYR-472;Trelagliptin (succinate);SYR 472 succinate;SYR472 succinate;SYR-472 succinate;Trelagliptin Succinate (SYR-472);SYR 111472 succinate;Trelagliptin succinat
Purity : 99%
CAS : 1029877-94-8
Place of Origin: China
Brand Name: NJBNSteroid
Usage: SYR-472 is an oral dipeptidyl peptidase IV inhibitor originated by Takeda. It is in phase III clinical trials for the treatment of type 2 diabetes.
Trelagliptin is a novel DPP-4 inhibitor that is being developed by Takeda. In contrast to alogliplitin, which is once a day, trelagliptin is a once-weekly oral agent which should provide patients with a convenient therapeutic alternative and has the potential to improve compliance. Takeda has commenced Phase III trials of trelagliptin in Japan for the treatment of Type 2 diabetes.